Mass spectrometry for small molecule pharmaceutical product development: A review

Mass Spectrometry Reviews

Volumn 30, Issue 3, 2011, Pages 479-490

  Gillespie, Todd A ^a   Winger, Brian E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

degradation products; dosage form; drug substance; impurities; mass spectrometry; product development

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS; CHEMICAL SYNTHESIS; DEGRADATION PRODUCTS; DEVELOPING PROJECTS; DOSAGE FORM; DRUG SUBSTANCE; FORMULATED PRODUCTS; IMPURITIES IN; MULTI-TIERED; PHARMACEUTICAL PRODUCTS; SMALL MOLECULES;

DEGRADATION; DRUG DOSAGE; DRUG PRODUCTS; MASS SPECTROMETERS; MASS SPECTROMETRY; SYNTHESIS (CHEMICAL);

PRODUCT DEVELOPMENT;

DRUG;

CHEMISTRY; DRUG DEVELOPMENT; MASS SPECTROMETRY; METHODOLOGY; REVIEW;

DRUG DISCOVERY; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS;

EID: 79954511536     PISSN: 02777037     EISSN: 10982787     Source Type: Journal    
DOI: 10.1002/mas.20289     Document Type: Review

References (67)

1. Ackermann BL, Berna MJ, Murphy AT,. 2002. Recent advances in use of LC/MS/MS for quantitative high-throughput bioanalytical support of drug discovery. Curr Top Med Chem 2: 53-66.
2. Antonovich RS, Keller PR,. 2002. Applicability of mass spectrometry to detect coeluting impurities in high-performance liquid chromatography. J Chromatogr A 971: 159-171. (Pubitemid 35247677)
3. Babjak M, Balogh G, Gazdag M, Görög S,. 2002. Estimation of impurity profiles of drugs and related materials: Part XXI. HPLC/UV/MS study of the impurity profile of ethynodiol diacetate. J Pharm Biomed Anal 29: 1153-1157. (Pubitemid 34756670)
4. Barbarin N, Henion JD, Wu Y,. 2002. Comparison between liquid chromatography-UV detection and liquid chromatography-mass spectrometry for the characterization of impurities and/or degradation products present in trimethoprim tablets. J Chromatogr A 970: 141-154. (Pubitemid 35286574)
5. Biesenthal T, Pace N, Impey G,. 2003. Impurity and Degradation Product Analysis: High Sensitivity Qualitative & Quantitative Analysis Using a Hybrid Triple-Quadrupole-Linear Ion Trap Mass Spectrometer. Proceedings of the 51st ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Montreal, Quebec, Canada.
6. Brewer E, Henion J,. 1998. Atmospheric pressure ionization LC/MS/MS techniques for drug disposition studies. J Pharm Sci 87: 395-402. (Pubitemid 28175798)
7. Bryant DK, Kingswood MD, Belenguer A,. 1996. Determination of liquid chromatographic peak purity by electrospray ionization mass spectrometry. J Chromatogr A 721: 41-51. (Pubitemid 26039814)
8. Chen YT, Wang FS, Ling YC, Liu HJ, Li L,. 2004. Enabling expeditious synthesis process monitoring and structural characterization of phthalocyanine compounds utilizing mass spectrometry. Proceedings of the 52nd ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Nashville, TN.
9. Chen H, Talaty NN, Takáts Z, Cooks RG,. 2005. Desorption electrospray ionization mass spectrometry for high-throughput analysis of pharmaceutical samples in the ambient environment. Anal Chem 77: 6915-6927. (Pubitemid 41547286)
10. Chen G, Pramanik BN, Liu Y-H, Mirza UA,. 2007. Applications of LC/MS in structure identifications of small molecules and proteins in drug discovery. J Mass Spectrom 42: 279-287. (Pubitemid 46426672)
11. Cody RB, Laramée JA, Durst HD,. 2005. Versatile new ion source for the analysis of materials in open air under ambient conditions. Anal Chem 77: 2297-2302. (Pubitemid 40562727)
12. Dimasi JA, Hansen RW, Grabowski HG,. 2003. The price of innovation: New estimates of drug development costs. J Health Econ 22: 151-185. (Pubitemid 36279392)
13. Eckers C, Haskins N, Langridge J,. 1997. The use of liquid chromatography combined with a quadrupole time-of-flight analyser for the identification of trace impurities in drug substance. Rapid Commun Mass Spectrom 11: 1916-1922. (Pubitemid 27518680)
14. Ermer J,. 1998. The use of hyphenated LC-MS technique for characterisation of impurity profiles during drug development. J Pharm Biomed Anal 18: 707-714. (Pubitemid 29057799)
15. Ermer J, Vogel M,. 2000. Applications of hyphenated LC-MS techniques in pharmaceutical analysis. Biomed Chromatogr 14: 373-383.
16. Fernández FM, Cody RB, Green MD, Hampton CY, McGready R, Sengaloundeth S, White NJ, Newton PN,. 2006. Characterization of solid counterfeit drug samples by desorption electrospray ionization and direct-analysis-in-real-time coupled to time-of-flight mass spectrometry. ChemMedChem 1: 702-705. (Pubitemid 44154357)
17. Freed AL, Kale U, Ando H, Rossi DT, Kingsmill CA,. 2004. Improving the detection of degradation products and impurities in pharmaceutical drug products by applying mass spectral and chromatographic searching. J Pharm Biomed Anal 35: 727-738. (Pubitemid 38757663)
18. Görög S,. 2000. Identification and determination of impurities in drugs, Vol. 4. Amsterdam, Netherlands: Elsevier Science B.V. p. 772.
19. Haskins NJ, Eckers C, Organ AJ, Dunk MF, Winger BE,. 1995. The use of electrospray ionization with Fourier transform ion cyclotron resonance mass spectrometry in the analysis of trace impurities in a drug substance. Rapid Commun Mass Spectrom 9: 1027-1030.
20. Henry ID, Park GHJ, Kc R, Tobias B, Raftery D,. 2008. Design and construction of a microcoil NMR probe for the routine analysis of 20-μL samples. Concepts Magn Reson 33B: 1-8.
21. Hong J, Hasan S, Broadus L, Veltri J, Fang J, Whellhan B,. 2003. Application of LC/MS and Photo Diode Array (PDA) Detection to Establish Impurity/Degradation Peak Correlations Within a Drug Product Matrix. Proceedings of the 51st ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Montreal, Quebec, Canada.
22. ICHQ3A (R2). 2008. Guidance for Industry: Impurities in New Drug Substance. June.
23. ICHQ3B (R2). 2006. Guidance for Industry: Impurities in New Drug Product. July.
24. ICHQ8. 2006. Guidance for Industry: Pharmaceutical Development. May.
25. Jansen PJ, Oren PL, Kemp CA, Maple SR, Baertschi SW,. 1998. Characterization of impurities formed by interaction of duloxetine HCl with enteric polymers hydroxypropyl methylcellulose acetate succinate and hydroxypropyl methylcellulose phthalate. J Pharm Sci 87: 81-85. (Pubitemid 28079266)
26. Jasper JP, Westenberger BJ, Spencer JA, Buhse LF, Nasr M,. 2004. Stable isotopic characterization of active pharmaceutical ingredients. J Pharm Biomed Anal 35: 21-30. (Pubitemid 38368857)
27. 13C NMR spectroscopy of urine for metabonomic studies. Anal Chem 74: 4588-4593. (Pubitemid 35006452)
28. Kolodsick KJ, Rossi DT, Kingsmill CA,. 2003. Breaking down barriers: Can LC-MS revolutionize the quantitation of drug product impurities? LCGC North Am 21: 468-479.
29. Lacey ME, Tan ZJ, Webb AG, Sweedler JV,. 2001. Union of capillary high-performance liquid chromatography and micorcoil nuclear magnetic resonance spectroscopy applied to the separation and identification of terpenoids. J Chromatogr A 922: 139-149. (Pubitemid 32703587)
30. Leader IP, Halket JM, Strife RJ, Varhaeghe B, Finch P,. 2002. Synthesis and identification of two potential oxidation degradation products of oxymetazoline. Proceedings of the 50th ASMS Conference on Mass spectrometry and Allied Topics. ASMS, Orlando, FL.
31. Lee M,. 2002. In:, Desiderio DM, Nibbering NMM, editors. LC/MS applications in drug development. New York: John Wiley and Sons. pp. 65-182.
32. Lee MS, Kerns EH,. 1999. LC/MS applications in drug development. Mass Spectrom Rev 18: 187-279. (Pubitemid 129660662)
33. Lewen N, Mathew S, Schenkenberger M, Raglione T,. 2004. A rapid ICP-MS screen for heavy metals in pharmaceutical compounds. J Pharm Biomed Anal 35: 739-752. (Pubitemid 38757664)
34. n in conjunction with mechanism-based stress studies in the elucidation of drug impurity structure: Rapid identification of a process impurity in betamethasone 17-valerate drug substance. J Pharm Biomed Anal 48: 1451-1456.
35. Marinković VD, Milojković SS, Nedeljković JM, Čomor JJ, Agbaba D, Živanov-Stakić D,. 1997. Gas chromatography-mass spectrometry determination of isosorbide 5-mononitrate and related impurities in raw materials and dosage formulations. J Pharm Biomed Anal 16: 425-429. (Pubitemid 27514384)
36. McEwen CN, McKay RG, Larsen BS,. 2005. Analysis of solids, liquids, and biological tissues using solids probe introduction at atmospheric pressure on commercial LC/MS instruments. Anal Chem 77: 7826-7831. (Pubitemid 41746252)
37. Mick JF, Winger BE,. 2004. LC/MS Quantitative API Drug Analysis Using Isotopically Labeled Internal Standard. Proceedings of the 52nd ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Nashville, TN.
38. Mistry N, Ismail IM, Smith MS, Nicholson JK, Lindon JC,. 1997. Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS. J Pharm Biomed Anal 16: 697-705. (Pubitemid 28044201)
39. Møller CW, Olsen H, Vo LR,. 2003. Characterization of Irganox 1010 Oxidation Products Using Electrospray MS/MS. Proceedings of the 51st ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Montreal, Quebec, Canada.
40. Morlock G, Ueda Y,. 2007. New coupling of planar chromatography with direct analysis in real time mass spectrometry. J Chromatogr A 1143: 243-251. (Pubitemid 46209102)
41. Moser H, Groeppelin AJ, Linder MW,. 2002. LC/MS in Pharmaceutical Drug Substance Development. Proceedings of the 50th ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Orlando, Florida.
42. n and accurate mass determination by ESI TOF. J Am Soc Mass Spectrom 16: 1670-1676. (Pubitemid 41345159)
43. Nicolas EC, Scholz TH,. 1998. Active drug substance impurity profiling: Part II. LC/MS/MS fingerprinting. J Pharm Biomed Anal 16: 825-836. (Pubitemid 28097410)
44. Nyadong L, Harris GA, Balayssac S, Galhena AS, Malet-Martino M, Martino R, Parry RM, Wang MD, Fernández FM, Gilard V,. 2009. Combining two-dimensional diffusion-ordered nuclear magnetic resonance spectroscopy, imaging desorption electrospray ionization mass spectrometry, and direct analysis in real-time mass spectrometry for the integral investigation of counterfeit pharmaceuticals. Anal Chem 81: 4803-4812.
45. Olsen BA, Kiehl DE,. 2006. Authentication and fingerprinting of suspect counterfeit drugs. Am Pharm Rev 9: 115-118.
46. 1H-NMR for mass-limited nanoliter-volume samples. Science 270: 1967-1970. (Pubitemid 126635493)
47. Qiu F, Norwood DL,. 2007. Identification of pharmaceutical impurities. J Liq Chrom Relat Tech 30: 877-935. (Pubitemid 46402180)
48. Qui F, Pennino S, Busacca CA, Norwood DL,. 2009. Identification of a process impurity during the synthesis of a nevirapine analogue HIV NNRT inhibitor using LC/MS and forced degradation studies. J Pharm Biomed Anal 49: 733-738.
49. Rashid MA, Gustafson KR, Crouch RC, Groweiss A, Pannel LK, Van QN, Boyd MR,. 2002. Application of high-field NMR and cryogenic probe technologies in the structural elucidation of Poecillastrin A, a new antitumor macrolide lactam from the sponge Poecillastra species. Org Lett 4: 3293-3296.
50. Robbins DK, Dodson PN, Buccilli LA, Mitchell D,. 2003. Utilizing capillary gas chromatography mass spectrometry to determine 4-benzotrifluoride t-butyl ether as a reaction by-product in fluoxetine synthesized using potassium t-butoxide as base. J Pharm Biomed Anal 31: 63-74. (Pubitemid 36120620)
51. Rourick RA, Volk KJ, Klohr SE, Spears T, Kerns EH, Lee MS,. 1996. Predictive strategy for the rapid structure elucidation of drug degradation products. J Pharm Biomed Anal 14: 1743-1752. (Pubitemid 26306913)
52. Suresh P, Basu PK,. 2008. Improving pharmaceutical product development and manufacturing: Impact on cost of drug development and cost of goods sold of pharmaceuticals. J Pharm Innov 3: 175-187.
53. Takáts Z, Wiseman JM, Bogdan G, Cooks RG,. 2004. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. Science 306: 471-473. (Pubitemid 39372443)
54. van de Kamp DAM, Faes PWCM, Jusic M, Fokkens RH, van Dongen WD,. 2004. Generic LC-MS: A "high throughput" tool to obtain a roadmap for drug substance and drug product selection. Proceedings of the 52nd ASMS Conference on Mass Spectrometry and Allied Topics. ASMS, Nashville, TN.
55. Vassort A, Barrett DA, Shaw PN, Ferguson PD, Szucs R,. 2005. A generic approach to the impurity profiling of drugs using standardised and independent capillary zone electrophoresis methods coupled to electrospray ionisation mass spectrometry. Electrophoresis 26: 1712-1723. (Pubitemid 40691486)
56. Volk KJ, Klohr SE, Rourick RA, Kerns EH, Lee MS,. 1996. Profiling impurities and degradation products of butorphanol tartrate using liquid chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry substructural techniques. J Pharm Biomed Anal 14: 1663-1674. (Pubitemid 26306904)
57. Vuletić M, Cindrić M, Koružnjak JD,. 2005. Identification of unknown impurities in simvastatin substance and tablets by liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 37: 715-721. (Pubitemid 40417745)
58. Wade N, Miller K,. 2005. Determination of active ingredient within pharmaceutical preparations using flow injection mass spectrometry. J Pharm Biomed Anal 37: 669-678. (Pubitemid 40417739)
59. Williams JP, Patel VJ, Holland R, Scrivens JH,. 2006. The use of recently described ionisation techniques for the rapid analysis of some common drugs and samples of biological origin. Rapid Commun Mass Spectrom 20: 1447-1456.
60. Windig W, Phalp JM, Payne AW,. 1996. A noise and background reduction method for component detection in liquid chromatography/mass spectrometry. Anal Chem 68: 3602-3606.
61. Winger BE, Kemp CAJ,. 2001. Characterization of pharmaceutical compounds and related substances by using HPLC FTICR-MS and tandem mass spectrometry. Am Pharm Rev 4: 55-56, 58, 60 62-63.
62. Wolff J-C, Thomson LA, Eckers C,. 2003. Identification of the "wrong" active pharmaceutical ingredient in a counterfeit Halfana™ drug product using accurate mass electrospray ionisation mass spectrometry, accurate mass tandem mass spectrometry and liquid chromatography/mass spectrometry. J Rapid Commun Mass Spectrom 17: 215-221. (Pubitemid 36164169)
63. Wu Y, Hwang TL, Algayer K, Xu W, Wang H, Procopio A, DeBusi L, Yang CY, Matuszewska B,. 2003. Identification of oxidative degradates of the TRIS salt of a 5,6,7,8-tetrahydro-1,8-naphthyridine derivative by LC/MS/MS and NMR spectroscopy - Interactions between the active pharmaceutical ingredient and its counterion. J Pharm Biomed Anal 33: 999-1015. (Pubitemid 37501003)
64. Xue G, Bendick AD, Chen R, Sekulic SS,. 2004. Automated peak tracking for comprehensive impurity profiling in orthogonal liquid chromatographic separation using mass spectrometric detection. J Chromatogr. A 1050: 159-171. (Pubitemid 39286240)
65. Zhao Z, Wang Q, Tsai EW, Qin XZ, Ip D,. 1999. Identification of losartan degradates in stressed tablets by LC-MS and LC-MS/MS. J Pharm Biomed Anal 20: 129-136. (Pubitemid 29206590)
66. n of degradates of a novel carbapenem antibiotic in an aqueous matrix. J Pharm Biomed Anal 29: 173-181. (Pubitemid 34621279)
67. Zhou H, Tai Y, Sun C, Pan Y,. 2005. Separation and characterization of synthetic impurities of triclabendazole by reversed-phase high-performance liquid chromatography/electrospray ionization mass spectrometry. J Pharm Biomed Anal 37: 97-107. (Pubitemid 40138721)